Open Access

Selective Epac2 antagonist attenuates cerebral infarction induced by secondary brain injury in rats

  • Authors:
    • Yuzo Kakei
    • Takahiro Igarashi
    • Ryuta Kajimoto
    • Katsunori Shijo
    • Hideki Oshima
    • Naoki Otani
    • Masatake Asano
    • Atsuo Yoshino
  • View Affiliations

  • Published online on: July 10, 2025     https://doi.org/10.3892/etm.2025.12922
  • Article Number: 172
  • Copyright: © Kakei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The impact of 1,3,5‑trimethyl‑2‑[(4‑methylphenyl)sulfonyl]‑benzene (ESI‑05), a specific antagonist of exchange protein directly activated by cyclic adenosine monophosphate 2 (Epac2), in mitigating secondary brain injury following cerebral hemorrhage and trauma has been established. However, to the best of our knowledge, the precise influence of ESI‑05 on apoptosis and cell death after cerebral infarction remains uncertain. The present study investigated the involvement of ESI‑05 in apoptosis and cell death using a rodent model of cerebral infarction induced by permanent middle cerebral artery (MCA) occlusion. Before permanent MCA occlusion, ESI‑05 was administered intraperitoneally at 8 mg/kg. Stroke volume, brain edema, and the levels of Epac2, phospho‑p38 and cleaved caspase 3 were evaluated. Apoptosis was detected by TUNEL staining. ESI‑05 administration reduced the infarct volume and water content, and reduced the levels of Epac2, phospho‑p38 and cleaved caspase 3 in the ischemic penumbra. Immunohistochemical staining confirmed that ESI‑05 attenuated apoptosis around the ischemic core. ESI‑05 administration reduced apoptosis and cell death around the ischemic core, resulting in amelioration of cerebral edema.
View Figures
View References

Related Articles

Journal Cover

September-2025
Volume 30 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kakei Y, Igarashi T, Kajimoto R, Shijo K, Oshima H, Otani N, Asano M and Yoshino A: Selective Epac2 antagonist attenuates cerebral infarction induced by secondary brain injury in rats. Exp Ther Med 30: 172, 2025.
APA
Kakei, Y., Igarashi, T., Kajimoto, R., Shijo, K., Oshima, H., Otani, N. ... Yoshino, A. (2025). Selective Epac2 antagonist attenuates cerebral infarction induced by secondary brain injury in rats. Experimental and Therapeutic Medicine, 30, 172. https://doi.org/10.3892/etm.2025.12922
MLA
Kakei, Y., Igarashi, T., Kajimoto, R., Shijo, K., Oshima, H., Otani, N., Asano, M., Yoshino, A."Selective Epac2 antagonist attenuates cerebral infarction induced by secondary brain injury in rats". Experimental and Therapeutic Medicine 30.3 (2025): 172.
Chicago
Kakei, Y., Igarashi, T., Kajimoto, R., Shijo, K., Oshima, H., Otani, N., Asano, M., Yoshino, A."Selective Epac2 antagonist attenuates cerebral infarction induced by secondary brain injury in rats". Experimental and Therapeutic Medicine 30, no. 3 (2025): 172. https://doi.org/10.3892/etm.2025.12922